BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC grew its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 3.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 87,180 shares of the company’s stock after acquiring an additional 3,198 shares during the period. Mizuho Markets Americas LLC’s holdings in BridgeBio Pharma were worth $2,220,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the company. Bfsg LLC lifted its stake in BridgeBio Pharma by 175.6% in the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after buying an additional 790 shares during the last quarter. Headlands Technologies LLC acquired a new position in BridgeBio Pharma during the second quarter worth about $48,000. Values First Advisors Inc. purchased a new position in BridgeBio Pharma in the third quarter valued at about $57,000. CWM LLC lifted its position in shares of BridgeBio Pharma by 132.9% during the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after acquiring an additional 1,964 shares during the period. Finally, EntryPoint Capital LLC purchased a new stake in shares of BridgeBio Pharma during the 1st quarter worth approximately $117,000. 99.85% of the stock is currently owned by hedge funds and other institutional investors.

BridgeBio Pharma Price Performance

Shares of BBIO stock opened at $23.72 on Friday. The firm’s 50-day simple moving average is $25.50 and its 200-day simple moving average is $26.41. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $44.32. The firm has a market cap of $4.48 billion, a P/E ratio of -9.84 and a beta of 1.09.

Insiders Place Their Bets

In other news, major shareholder Genetic Disorder L.P. Kkr sold 5,800,000 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $25.75, for a total value of $149,350,000.00. Following the transaction, the insider now directly owns 25,260,971 shares in the company, valued at $650,470,003.25. This trade represents a 18.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Brian C. Stephenson sold 4,155 shares of the business’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $24.69, for a total value of $102,586.95. Following the sale, the chief financial officer now owns 85,192 shares of the company’s stock, valued at $2,103,390.48. The trade was a 4.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,831,544 shares of company stock valued at $150,128,821 over the last quarter. Company insiders own 24.66% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on BBIO shares. Leerink Partners lowered their target price on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Piper Sandler initiated coverage on shares of BridgeBio Pharma in a research report on Wednesday, September 4th. They set an “overweight” rating and a $46.00 target price for the company. Oppenheimer assumed coverage on shares of BridgeBio Pharma in a report on Thursday, October 3rd. They issued a “market perform” rating on the stock. Scotiabank raised their price objective on shares of BridgeBio Pharma from $44.00 to $45.00 and gave the stock a “sector outperform” rating in a research note on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $43.00 target price on shares of BridgeBio Pharma in a research note on Friday, October 25th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $47.57.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.